Scientific & Clinical Advisors

JOSEPH MILETICH, MD, PHD

Former SVP, Research Sciences, at Merck
linkedin-icon-green

Joseph Miletich, MD, PhD, is a former SVP, Research Sciences, at Merck. He has more than 20 years of combined experience at Merck and Amgen leading programs through Discovery Research, Preclinical Development and Translational Medicine/Early Development. At both companies, Dr. Miletich focused on building teams and investing in technologies, partnerships and acquisitions to enable capitalizing on new insights into biology regardless of therapeutic area or modality. Dr. Miletech currently serves as advisor and board director to several companies and firms. Most recently, Dr. Miletich was Merck Research Laboratories’ senior vice president of research sciences and is currently senior scientific advisor to Merck’s CEO, an advisor to Recursion, and a director to Flame Biosciences, among other roles. . Prior to his last 8+  years at Merck Research Laboratories, Dr. Miletich served as senior vice president of research and development at Amgen. 

Dr. Miletich received his M.D. and Ph.D. degrees from Washington University in St. Louis and pursued clinical training in internal medicine at the University of California in San Francisco. Subsequently he joined the faculty at Washington University, pursued subspecialty training in clinical hematology and in laboratory medicine, and developed a leading research effort in hemostasis and thrombosis. Over a 17 year career, he rose through the ranks to become Professor of Medicine and Pathology and Head of the Division of Laboratory Medicine at Washington University, in which capacity he was responsible for the combined laboratories of the Barnes-Jewish Hospital system, one of the nation’s largest clinical laboratories.

Learn more about Joseph

LinkedIn

Nicholas-E.-Johnson

Nicholas E. Johnson, MD, MSCI, FAAN

Neuromuscular Clinical Advisor; Professor and Vice Chair of Research, Neuromuscular Diseases, VCU
linkedin-icon-green

Nicholas E. Johnson, MD, MSCI, FAAN is an associate professor, division chief of neuromuscular, and vice chair of research in the department of neurology at Virginia Commonwealth University with a focus in inherited neuromuscular disorders. He received his undergraduate degree in molecular and cellular biology and psychology at the University of Arizona. He then obtained his medical degree at the University of Arizona. He completed his neurology residency and combined fellowship in neuromuscular medicine and experimental therapeutics at the University of Rochester. His laboratory is focused on identifying the pathogenesis of myotonic dystrophy, the limb girdle muscular dystrophies, and facioscapulohumeral muscular dystrophy and identifying appropriate clinical endpoints for these conditions. Johnson conducts therapeutic trials in many other inherited nerve and muscle disorders.

Research Expertise

Translational laboratory focused on identifying genetic modifiers across muscular dystrophies, and developing clinical endpoints and patient reported outcomes for myotonic dystrophy, facioscapulohumeral muscular dystrophy, and the limb girdle muscular dystrophy. The laboratory uses cellular models to identify changes in RNA splicing in myotonic dystrophy.

Learn more about Dr. Johnson

LinkedIn
VCU

John W. Day, MD, PhD

MD, PhD, Professor of Neurology and Pediatrics Director, Division of Neuromuscular Medicine Stanford University School of Medicine
linkedin-icon-green

Since 2011 John has been Professor of Neurology, Pediatrics (Genetics) and Pathology at Stanford University, where he is Director of the Division of Neuromuscular Medicine. He received his MD from the University of Minnesota, and PhD in Neuroscience from Albert Einstein College of Medicine, where he studied neuronal electrophysiology, synaptic physiology and plasticity.  After completing neurology and neuromuscular training at UCSF, he was Professor of Neurology, Pediatrics and Genetics at the University of Minnesota, where he founded and directed the Paul and Sheila Wellstone Muscular Dystrophy Center. 

John has investigated the genetic causes and multisystemic effects of neuromuscular disorders and has more than 35 years of experience designing and directing clinical trials of novel therapeutics.  He spearheaded clinical research on spinal muscular atrophy (SMA) at Stanford, which resulted in the approval of antisense and AAV-gene replacement treatments, and led to nationwide newborn screening for SMA and institution of neonatal genetic treatment.

Learn more about John

LinkedIn

Tina Duong PT, PHD

Senior Research Scientist, Director Clinical Outcomes Research and Development (CORD) Stanford University, Neuromuscular Division
linkedin-icon-green


Tina Duong is the Director of clinical outcomes research and development at Stanford University Neuromuscular division. Clinically, she is a physical therapist with 20 years of clinical experience in evaluating, treating and validating clinical outcomes for patients with neuromuscular disease. 

Her clinical and research interests are in developing, refining and understanding impacts of muscle imbalances and pathology on function and performance. Her work has contributed to improved understanding and characterization of disease phenotypes impacting clinical trial design and care management.

Currently, her research focuses on the effect of exercise and physical activity on human movement and disease physiology. She hopes to integrate technology and digital biomarkers as a complementary tool to performance based measures used in trials, in the clinic and remotely. She enjoys working on collaborative diverse inter-disciplinary teams, mentorship and creating patient focused solutions to improve the quality of life for individuals with neuromuscular disease.

Learn more about Tina

LinkedIn

Peter-Jackson

Peter Jackson, PhD

Professor, Stanford School of Medicine, former Director, Genentech
linkedin-icon-green

Peter Jackson is a Professor in the Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, at the Stanford University School of Medicine. Dr. Jackson returned to Stanford in 2013 after eight years as a Staff Scientist and Director at Genentech Inc. in S. San Francisco, California. At Genentech, he helped define and implement the development of therapeutics for cancer pathways including cell cycle checkpoints, stress pathways, and tumor metabolism. Before joining Genentech in 2005, he spent 10 years on the faculty at Stanford University School of Medicine. His laboratory has been involved in studies of cell cycle biochemistry, regulation of the cancer by kinases and phosphatases, the ubiquitin-proteasome system, and the discovery of a new physiological class of competitive (“pseudosubstrate”) E3 ubiquitin ligase inhibitors, exemplified by the APC/C regulator Emi1.

Since 2005, his lab has focused on signaling through the primary cilium, using proteomic approaches to define regulatory networks and new disease genes. More broadly, the lab has connected many proteins defective in human diseases and cancer to new complexes and pathways, with a view to discovering molecular signatures for diagnostics and therapeutic development. His research has earned him numerous visiting lectureships and honors, including awards from the Baxter Foundation, Howard Hughes Medical Institute, the American Cancer Society, the Pluto Society, and being a Stanford Hume Faculty Scholar and a Kirsch Scholar, and elected a Fellow of the American Association for the Advancement of Science (in 2008).

Learn more about Peter

LinkedIn
Stanford School of Medicine

Christopher Kirk, PhD

Co-Founder, President and Chief Scientific Officer of Kezar Life Sciences
linkedin-icon-green

Christopher Kirk, PhD is an independent director, scientific and strategic advisor to Juvena Therapeutics. He is the  co-founder, President and Chief Scientific Officer of Kezar Life Sciences, a publicly traded company developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins. Dr. Kirk is an immunologist and tumor biologist by training. Prior to founding Kezar, he was the Vice President of Research at Onyx Pharmaceuticals where he played a key leadership role in the discovery and development of 2 proteasome inhibitors, including carfilzomib (KYPROLIS™), currently approved for the treatment of multiple myeloma. Dr. Kirk has authored multiple publications in several select journals including Cell, Nature Medicine, and Nature Reviews and is listed as an inventor on over 40 patents. He sits on the scientific advisory board at C4 Therapeutics, Avidity Biosciences, Rain Therapeutics, the Institute of Applied Clinical Science at the M.D. Anderson Cancer Center as well as the leadership council of the Life Sciences Institute of the University of Michigan.

Dr. Kirk received his B.S. in Biochemistry from the University of California, Davis, and his Ph.D. in Cellular and Molecular Biology from the University of Michigan.

Learn more about Christopher

LinkedIn
Christopher Kirk, PhD

David-Schaffer

David Schaffer, PhD

Professor, UC Berkeley, Director, Berkeley Stem Cell Center, co-founder, 4D Molecular Therapeutics; Director, Bakar BioEnginuity Hub
linkedin-icon-green

David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at UC Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. In addition, he is Co-Founder, Acting CSO, and Co-Chairman of 4D Molecular Therapeutics.

At UC Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration, work that includes novel approaches for molecular engineering and evolution of new viral vectors as well as new technologies to investigate and control stem cell fate decisions.

Professor Schaffer served as Dr. Yousef’s co-thesis advisor (2008-2013).

Learn more about David

LinkedIn
UC Berkeley

Irina-Conboy

Irina Conboy, PhD

Professor, Bioengineering, UC Berkeley

Irina Conboy is a Professor at the University of California, Berkeley in the Department of Bioengineering. Her discovery of the rejuvenating effects of young blood through parabiosis in a seminal paper published in Nature in 2005 paved the way for a thriving field of rejuvenation biology. The Conboy lab currently focuses on broad rejuvenation of tissue maintenance and repair, stem cell niche engineering, elucidating the mechanisms underlying muscle stem cell aging, directed organogenesis, and making CRISPR a therapeutic reality.

Professor Conboy served as Dr. Yousef’s co-thesis advisor (2008-2013).

Learn more about Irina

CONBOY LABORATORY
UC Berkeley

Joe-Wu

Joe Wu, MD, PhD

Professor, Stanford School of Medicine, Director, Stanford Cardiovascular Institute
linkedin-icon-green

Joseph C. Wu, MD, PhD, is Director of the Stanford Cardiovascular Institute and Simon H. Stertzer Endowed Professor in the Departments of Medicine (Cardiology) and Radiology at Stanford School of Medicine. Dr. Wu received his medical degree from Yale. He completed his medicine internship, residency, and cardiology fellowship (STAR program) at UCLA. He obtained his PhD in the Department of Molecular & Medical Pharmacology with Dr. Sam Sanjiv Gambhir. His clinical interests include adult congenital heart disease and cardiovascular imaging.

His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs) with a focus on cardiovascular disease mechanisms and the implementation of precision medicine for prevention and treatment of cardiovascular patients. His lab uses a combination of genomics, stem cells, cellular & molecular biology, physiological testing, and molecular imaging technologies. Dr. Wu has published >400 manuscripts with H-index of 101 on Google scholar and recognition as top 1% of highly cited researchers in Web of Science (2018, 2019 & 2020). Among his trainees, >30 of them are principal investigators in the US or abroad.

Dr. Wu has received numerous awards, including National Institutes of Health (NIH) Director’s New Innovator Award, NIH Roadmap Transformative Award, American Heart Association (AHA) Innovative Research Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama, AHA Established Investigator Award, Burroughs Wellcome Foundation Innovation in Regulatory Science Award, AHA Merit Award, and AHA Distinguished Scientist Award. Dr. Wu serves on the Scientific Advisory Board for the Keystone Symposia, FDA Cellular, Tissue, and Gene Therapies Advisory Committee, AHA National Board of Directors, and Chair of the AHA National Research Committee.

Dr. Wu is an elected member of American Society of Clinical Investigators (ASCI), Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association of Physicians (AAP), American Association for the Advancement of Science (AAAS), and National Academy of Medicine (NAM).

In addition, he has been scientific co-founder of several startups.

Learn more about Joe

Stanford School of Medicine
LinkedIn

Business Advisors

Matthew-Fust

Matthew Fust, MBA

Former CFO Onyx, Jazz, ALZA (merged with J&J); Board member, Neumora, Arsenal Bio, Atara, Ultragenyx
linkedin-icon-green

Matthew is an advisor to life sciences companies, executive teams and investors. From 2009 through 2013, he was CFO of Onyx Pharmaceuticals, culminating in the company’s acquisition by Amgen. He previously served as CFO of Jazz Pharmaceuticals (2003 – 2008), CFO of Perlegen Sciences (2002 – 2003), and CFO of ALZA Corporation, where he was an executive from 1996 through the company’s acquisition by Johnson & Johnson in 2001. Prior to joining ALZA, Matthew was a member of the healthcare strategy consulting practice at Andersen Consulting (now Accenture). 

He serves on the boards of directors of Atara Biotherapeutics, Crinetics Pharmaceuticals and Ultragenyx Pharmaceuticals. He is also an advisor to Out Leadership/Quorum and Women In Bio.

Matthew holds an undergraduate degree from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business.

Learn more about Matthew

LinkedIn

ameet-mallik

Ameet Mallik, MBA

CEO, ADC Therapeutics, Former EVP, US Oncology at Novartis, McKinsey, Wharton
linkedin-icon-green

Ameet Mallik is CEO of ADC Therapeutics, and a member of the Board of Directors of Atara Biotherapeutics. Prior to that, Mr. Mallik served as Executive Vice President and Head, U.S. Oncology of Novartis. In this role, Mr. Mallik was responsible for Novartis’ commercial and medical oncology operations in the United States. Mr. Mallik also served as Global Head, Marketing, Value and Access, and as Head, Latin America and Canada, both for Novartis Oncology. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables. Mr. Mallik previously worked as an Associate Principal at McKinsey and Company. Mr. Mallik holds an M.B.A. from The Wharton School at the University of Pennsylvania, and an M.S. in Biotechnology and B.S. in Chemical Engineering, both from Northwestern University.

Learn more about Ameet

LinkedIn

Mike-Nohaile

Mike Nohaile, PhD

CEO, Prellis Biologics, former CSO, Generate Biomedicines; Former SVP Amgen, Novartis, McKinsey, UC Berkeley, MIT
linkedin-icon-green

Mike Nohaile, PhD, is Chief Executive Officer at Prellis Biologics and former Senior Vice President of Strategy, Commercialization & Innovation at Amgen Inc. Dr. Nohaile joined Amgen as Vice President of Strategy in December 2012. Prior to Amgen, he served as the Head and General Manager of the Molecular Diagnostics Business Unit at Novartis. He served Novartis as the Head of Corporate Strategy and Head of Pharmaceutical Strategy.

Mike began his career at McKinsey & Company, as partner in the New Jersey office, where he worked extensively in the healthcare area with a particular focus on diagnostics, devices and pharmaceuticals. He has a doctorate in molecular and cell biology from University of California, Berkeley and he was a postdoctoral fellow at MIT in the Department of Biology.

Learn more about Mike

LinkedIn

Mark-Leslie

Mark Leslie

Former CEO, Vertias; Stanford GSB, Stanford Healthcare
linkedin-icon-green

Mark Leslie is a Lecturer at the Stanford Graduate School of Business where he teaches courses in Entrepreneurship, Ethics and Sales Organization. He is also the managing director of Leslie Ventures, a private investment company, and serves on the boards of public, private and nonprofit organizations.

Mark Leslie was Co-Founder and Chairman and CEO of Veritas Software. During his tenure as CEO, the company went from 12 employees to 6,000 employees, and from a revenue base of $95,000 per year to $1,500,000,000 per year. In 2000, Veritas was the 10th largest independent software company by revenue, third largest by market capitalization, and achieved the distinction of becoming a Fortune 1000 company.

From 1980 until 1990 he served as president and chief executive officer of two Silicon Valley high-tech start-up companies. His prior experience included sales management, sales executive, systems engineer, and software engineer focused on operating systems.

Mark currently serves on the boards of, or is an advisor to. a number of high-tech and biotech companies. Mark is also on the boards of Stanford Health Care, New York University and the Leslie Family Foundation.

Mark received a Bachelor of Arts degree in physics and mathematics from New York University in 1966 and completed Harvard Business School’s Program for Management Development (PMD)in 1980.

Learn more about Mark

Stanford Business School
LinkedIn